French pharmaceutical company Sanofi is strategically positioning itself in the Indian market to achieve a more equitable share. With plans to introduce new medications, localize production, and collaborate with domestic pharmaceutical firms, Sanofi aims for a stronger foothold in India. Managing Director Rodolfo Hrosz emphasised the company’s commitment to preparing for accelerated growth in the country, citing India’s immense potential.
Highlighting the significance of India as a key market, Hrosz underscores the company’s focus on addressing the diabetes epidemic in the country. Sanofi intends to enter the premix insulin segment with Soliqua, offering tailored solutions for better diabetes management. Additionally, Hrosz mentioned about a robust pipeline of twelve different products slated for launch, including Dupixent for atopic dermatitis treatment.
Sanofi, currently has collaborations with fifteen contract manufacturing organizations in India, complemented by its manufacturing facility in Goa. The company plans to further leverage its production capabilities.
As reported by businessline, to expand its reach, Sanofi Healthcare India has partnered with leading Indian pharmaceutical companies such as Cipla, Dr. Reddy’s Laboratories, and Emcure. The collaborative approach aligns with Sanofi’s vision to enhance accessibility to its products across India.
